ResMed Inc.
14040 Danielson Street
Poway
California
92064
United States
Tel: 858-746-2400
Fax: 858-746-2900
Website: http://www.resmed.com/
Email: reception@resmed.com
330 articles about ResMed Inc.
-
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
3/15/2024
ResMed, the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day, shedding light on the critical sleep challenges faced by people around the world.
-
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
3/6/2024
ResMed announced the U.S. launch of the AirFit F40, an ultra-compact, full-face mask offering the comfort of smaller masks without sacrificing performance in order to help improve sleep apnea therapy compliance.
-
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
2/12/2024
ResMed launched its AirCurve 11 series devices, the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure and expiratory positive airway pressure, combined with digital technology to make it easier for healthcare providers to treat sleep apnea and to help patients start and stay on therapy.
-
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
1/24/2024
ResMed Inc. announced results for its quarter ended December 31, 2023.
-
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
1/3/2024
ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday, January 24, 2024, after the New York Stock Exchange closes.
-
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
12/27/2023
ResMed announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. at the Westin St. Francis in San Francisco, CA.
-
ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
12/20/2023
ResMed is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body.
-
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
10/26/2023
ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2023.
-
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
10/5/2023
ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday, October 26, 2023, after the New York Stock Exchange closes.
-
Nyxoah Announces Partnership with ResMed in Germany
9/28/2023
Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company has entered into a partnership with ResMed Germany to increase OSA awareness and therapy penetration in the German market.
-
ResMed Announces Participation in Upcoming Conferences
9/5/2023
ResMed announced its participation in two upcoming conferences.
-
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023
8/3/2023
ResMed Inc. announced results for its quarter ended June 30, 2023.
-
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
7/6/2023
ResMed announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on Thursday, August 3, 2023, after the New York Stock Exchange closes.
-
ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
6/5/2023
ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, beginning at approximately 9:20 a.m. (Pacific Daylight Time) at the Waldorf Astoria Monarch Beach in Dana Point, CA.
-
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2023
4/27/2023
ResMed Inc. announced results for its quarter ended March 31, 2023.
-
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
4/6/2023
ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2023 on Thursday, April 27, 2023, after the New York Stock Exchange closes.
-
ResMed Chief Administrative Officer and Global General Counsel to Retire
3/30/2023
ResMed announced that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023.
-
ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum
3/15/2023
ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will join a fireside chat at the 2023 KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, beginning at approximately 3:45 p.m. (Eastern Daylight Time) via webcast.
-
ResMed Announces Participation in the Oppenheimer 33rd Annual Healthcare Conference
3/7/2023
ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, beginning at approximately 11:20 a.m. (Eastern Daylight Time) via webcast.
-
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023
1/26/2023
ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2022.